HomeInsightsStock Comparison

Marksans Pharma Ltd vs Piramal Pharma Ltd Stock Comparison

Marksans Pharma Ltd vs Piramal Pharma Ltd Stock Comparison

Last Updated on: Dec 21, 2025

Key Highlights

  • The Latest Trading Price of Marksans Pharma Ltd is ₹ 182.85 as of 19 Dec 15:30.
  • The P/E Ratio of Marksans Pharma Ltd changed from 4.7 on March 2020 to 26.5 on March 2025 . This represents a CAGR of 33.41% over 6 yearsThe P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 325.4 on March 2025 . This represents a CAGR of -42.71% over 2 years.
  • The Market Cap of Marksans Pharma Ltd changed from ₹ 568.95 crore on March 2020 to ₹ 10076 crore on March 2025 . This represents a CAGR of 61.45% over 6 yearsThe Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 29763 crore on March 2025 . This represents a CAGR of 53.90% over 3 years.
  • The revenue of Marksans Pharma Ltd for the Sep '25 is ₹ 741.98 crore as compare to the Jun '25 revenue of ₹ 625.63 crore. This represent the growth of 18.6% The revenue of Piramal Pharma Ltd for the Sep '25 is ₹ 2124 crore as compare to the Jun '25 revenue of ₹ 2031 crore. This represent the growth of 4.56%.
  • The ebitda of Marksans Pharma Ltd for the Sep '25 is ₹ 166.07 crore as compare to the Jun '25 ebitda of ₹ 105.76 crore. This represent the growth of 57.03% The ebitda of Piramal Pharma Ltd for the Sep '25 is ₹ 239.08 crore as compare to the Jun '25 ebitda of ₹ 204.41 crore. This represent the growth of 16.96%.
  • The net profit of Marksans Pharma Ltd changed from ₹ 70.44 crore to ₹ 99.14 crore over 10 quarters. This represents a CAGR of 14.65% The net profit of Piramal Pharma Ltd changed from ₹ -98.58 crore to ₹ -99.22 crore over 10 quarters. This represents a CAGR of 0.26% .
  • The Dividend Payout of Marksans Pharma Ltd changed from 10.8 % on March 2020 to 19.26 % on March 2025 . This represents a CAGR of 10.12% over 6 yearsThe Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 2.68 % on March 2025 . This represents a CAGR of -37.94% over 4 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Marksans Pharma Ltd

  • Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982.
  • Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005.
  • The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
  • The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
  • Marksans Pharma Limited (formerly M/s.

About Piramal Pharma Ltd

  • Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
  • It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
  • In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
  • It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

Marksans Pharma Ltd News Hub

News

Relonchem receives UK MHRA's approval for Cetirizine Dihydrochloride 1 mg/ml Oral Solution

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Ma...

Read more

20 Nov 2025 14:00

News

Marksans Pharma receives USFDA approval for Loperamide Hydrochloride tablets

Marksans Pharma announced USFDA final approval of the Company's wholly owned subsidiary Ma...

Read more

19 Nov 2025 11:32

News

Marksans Pharma's arm gets USFDA approval for Loperamide Hydrochloride 2mg tablets

The approved product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tabl...

Read more

19 Nov 2025 13:30

News

Relonchem receives UK MHRA's marketing approval for two products

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Ma...

Read more

17 Nov 2025 11:38

News

Marksans Pharma's Goa unit clears USFDA inspection

Marksans Pharma announced that a current Good Manufacturing Practice (cGMP) inspection was...

Read more

10 Nov 2025 14:08

News

Marksans Pharma gains after USFDA clears Goa facility with zero observations

In a filing exchange filing, the company stated that the inspection was carried out at its...

Read more

10 Nov 2025 13:03

Piramal Pharma Ltd News Hub

News

Piramal Pharma's Lexington facility receives four USFDA observations

The inspection took place from 3 to 10 December 2025. At the end of the inspection, the US...

Read more

12 Dec 2025 12:24

News

Piramal Pharma Ltd down for fifth straight session

Piramal Pharma Ltd is down for a fifth straight session today. The stock is quoting at Rs ...

Read more

11 Nov 2025 13:35

News

Piramal Pharma reports dismal Q2 numbers

Revenue from operations for the period under review declined 8.83% year-on-year (YoY) to R...

Read more

06 Nov 2025 12:59

News

Piramal Pharma to discuss results

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 5 November ...

Read more

24 Oct 2025 14:07

News

Piramal Pharma Ltd spurts 2.86%, rises for third straight session

Piramal Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 202...

Read more

23 Oct 2025 13:05

News

Piramal Pharma Solutions opens dedicated OSD form suite at its facility in Sellersville, Pennsylvania

Piramal Pharma Solutions and NewAmsterdam Pharma Company N.V. today announced the opening ...

Read more

21 Aug 2025 19:49

SWOT Analysis Of Piramal Pharma Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Marksans Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Piramal Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Marksans Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Marksans Pharma Ltd and Piramal Pharma Ltd

Which company has a larger market capitalization, Marksans Pharma Ltd or Piramal Pharma Ltd?

Market cap of Marksans Pharma Ltd is 8,286 Cr while Market cap of Piramal Pharma Ltd is 22,743 Cr

What are the key factors driving the stock performance of Marksans Pharma Ltd and Piramal Pharma Ltd?

The stock performance of Marksans Pharma Ltd and Piramal Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Marksans Pharma Ltd and Piramal Pharma Ltd?

As of December 21, 2025, the Marksans Pharma Ltd stock price is INR ₹182.85. On the other hand, Piramal Pharma Ltd stock price is INR ₹171.1.

How do dividend payouts of Marksans Pharma Ltd and Piramal Pharma Ltd compare?

To compare the dividend payouts of Marksans Pharma Ltd and Piramal Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions